Multicompartment Lipid Nanocarriers for Targeting of Cells Expressing Brain Receptors - Self-Assembled Supramolecular Architectures: Lyotropic Liquid Crystals - page 339

(a) (b)

a b

a b

c c

Figure 11.10 Confocal microscopy images (oil objective 63×/1.4) of cells fi xed on
glass slides in control experiments: (a) fl uorescence image (zoom 2×), (b) Nomarski
(DIC) image, and (c) superposition of the images (a) and (b). Images of untreated
cells (A), and of cells treated with retinoic acid (10 μM) during 5 days and incubated
with a secondary antibody in the absence of a primary antibody (B). Image size:
73.25 × 73.25 μ m 2 . The scale bar corresponds to 10 μ m.

IgG (primary antibody). An overlay of the fl uorescence and the Nomarski
images of the cells was achieved. Thus, the SH-SY5Y cells were demonstrated
to express the TrkB receptor of the neurotrophin BDNF upon treatment with
retinoic acid (10 M) for 4 days. The expression of the BDNF receptor could

be demonstrated also by other methods such as the Western blot analysis of
ribonucleic acid (RNA) of the protein (Kaplan et al., 1993, Encinas et al., 2000,
Kou et al., 2008; Matsumoto et al., 1995).

μ

11.4.3.2 Cellular Viability upon Treatment with Neurotrophic Peptide
BDNF and Multicompartment Liquid Crystalline Lipid Nanocarriers, as
Evidenced by MTT Tests The viability of differentiated SH-SY5Y cells
after 5 days of treatment with retinoic acid (10

μ M) was estimated to be

44 6% compared to untreated cells. The obtained result reveals an essential

decrease in the cell proliferation in the absence of neuroprotective treatment.
Therefore, the created model with differentiated neuroblastoma cells is sub-
stantially relevant to the study of neuroprotective strategies in view of poten-
tial therapies of neurodegenerative diseases.
MTT tests were accomplished with differentiated SH-SY5Y cells at
decreasing concentrations of MO/DOPE-PEG 2000 /OA (83/2/15 mol %),
MO/DOPE - PEG 2000 /EPA (83/2/15 mol %), and DMPC/DOPE - PEG 2000 /EPA
(83/2/15 mol %) lipid nanocarrier samples of analogous compositions. The
initial number of cells for the MTT tests was 20,000 cells/well/200

±

μ l. Figure